before “stepping up” to more expensive alternatives is permissible if medically appropriate. For
commonly prescribed drugs, the adjudication process may systematically assume a failed treatment based
on previous claims history. This automated process reduces the need for prior authorization requests. To
see how plans apply Step Therapy (ST) protocols, please refer to the attached appendices.
1) Step Therapy (ST) protocols specifically indicate the quantity and name(s) of the preferred
alternative drug(s) that must be tried and failed within a designated time period.
2) At point-of-sale, claims history is reviewed electronically for first-line therapy. If the member has
met the ST criteria, they will not be subject to the Drug Evaluation Review (“DER”) process and
will receive the ST medication.
3) Requests for exceptions to drugs listed on the PDL requiring ST shall be reviewed for approval.
NJ FamilyCare MCOs rely on ST and do not have prescription “tiers”. The use of tiers is commonly used in
commercial plans as a way for MCOs to separate the drugs they cover within classes based on safety and
cost. Generally, secondary tiers require higher copayment amounts for prescription drugs in addition to
the need for prior authorization. NJ FamilyCare does not allow copayments. Therefore, the MCOs rely on
Step therapy. If a prescription for mental health drugs has not met the fail requirements, or the prescriber
wants to bypass the lower step drug(s), a prior authorization is required. As per an executive order,
substance use medication assisted treatment may not be prior authorized with the exception of non-
formulary medications. The prescriber must contact the MCO and provide the required information
supporting a non-formulary drug. If the correct information is received, the MCO has 24 hours to make a
decision. If the decision supports the prescriber, the authorization is given and the beneficiary receives
their drug. If the decision does not, the prescriber may prescribe the alternative in formulary medication.
These decisions are required to be based on medical necessity. However, ST is not applied any more
stringently for BH/SUD than it is for M/S prescriptions. All adverse determinations are appealable based
on best practice guidelines and medical necessity. All prescribers have the right to call and speak with the
medical director at the plan responsible for the negative decision. If unsuccessful, they may go to an
outside peer for an independent decision.
Managed Care providers use this utilization management tool for drugs that have a high potential for
inappropriate use. Step therapy is essential to maintain our recipients’ safety and health. To ensure step
therapy protocol remains current, these protocols are developed and reviewed at least annually. They
indicate the criteria that must be met in order for the drug to be authorized (e.g., specific diagnoses, lab
values, trial and failure of alternative drug(s), allergic reaction to preferred product, etc.).
Pharmacy services contain several measures beyond step therapy which include prior authorization.
Authorization for certain pharmaceutical products ensures that providers comply with pharmacy practice
standards, drug utilization review, internal medication error identification systems, medical therapy
management programs, and pharmacy and therapeutics committee recommendations. This helps to
ensure that recipients receive safe, high-quality, cost-effective pharmaceutical therapy. All prior
authorizations, requirements, and edit restrictions can be overridden by the State or MCO pharmacy
department staff once medical necessity is established and safety is assured. Therefore this NQTL is a soft
limit which is applied equally for M/S and BH/SUD pharmaceutical services. There is no dollar or quantity
limit and usage can be extended beyond DURB limits if clinically indicated. Therefore, this category of
service meets the parity standard established by MHPAEA.
Emergency BH/SUD